-
In a systematic review and meta-analysis of prospective studies examining the association between mental stress-induced myocardial ischemia (MSIMI) and adverse outcome events in patients with stable CAD, all existing investigations point to an approximate doubling of cardiovascular risk in patients with MSIMI.
-
-
Makani H, et al. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: A meta-analysis.
-
The trouble with the expense of treating hepatitis C virus (HCV) infections is that very few patients are acutely choking on it, since the largest pool of HCV patients are asymptomatic. Progression to end-stage liver disease, liver transplantation, and hepatocellular carcinoma the three most dreaded HCV consequences may seem distant to the asymptomatic or even modestly symptomatic patient.
-
The FDA has approved a mu-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC). Naloxegol is a pegylated derivative of naloxone which acts on peripheral (e.g., gut) mu-receptors. It is marketed by AstraZeneca Pharmaceuticals as Movantik.
-
Migraine is associated with multiple disorders, including irritable bowel syndrome, restless legs syndrome, and non-alcoholic fatty liver disease. Understanding how these disparate disorders link to migraine may lead to an increased understanding of the pathogenesis of this complex neurological condition.
-
Interpret the ECG in the Figure obtained from a patient with new-onset chest pain. Localize the area(s) of acute infarction. Which coronary artery is likely to be acutely occluded?
-
Pain and Fall Risk Assessment in Cognitively Impaired Nursing Home Residents; PSA Screening: Maybe You Saw the Movie NeverEnding Story?; Screening for Lung Cancer in Asbestos Workers
-
-
The FDA has approved the first free fatty acid form of omega-3. Previous formulations have been ethyl esters of omega-3-acids. The omega-3-carboxylic acid is a fish oil-derived mixture of 50-60% eicosapentaenoic acid (EPA) and 15-25% docosahexaenoic acid (DHA) along with other potentially active omega-3 fatty acids. It is marketed by AstraZeneca as Epanova.